glp-1 and gerd What is the treatment for gastroesophageal reflux disease (GERD) in patients using Glucagon-like peptide (GLP)-1 analogues? Risk of GERD and Barrett's

T.VeronicaE.HartawanI

While empagliflozin primarily targets blood sugar control and cardiovascular risks, its direct impact on reducing diabetes-related blindness is less straightforward

However, incorrect concentrations or excessive dosage levels can disrupt baseline circadian rhythms and cause short-term lethargy patterns

It does so by acting as an agonist a substance that mimics the naturally occurring hormone by attaching to the same cell receptors in the brain and producing a similar or enhanced response in the body, including improved insulin release, lower appetite and slow digestion

D., Crema, L

Petta S, Kim K, Targher G, et al